| scholarly article | Q13442814 |
| P50 | author | Donal Gorman | Q89413294 |
| P2093 | author name string | Katrina Gore | |
| Richard P Butt | |||
| Geert Jan Groeneveld | |||
| Justin L Hay | |||
| Peter Loudon | |||
| Pinky Dua | |||
| Guido van Amerongen | |||
| Pieter Siebenga | |||
| P2860 | cites work | NGF induces non-inflammatory localized and lasting mechanical and thermal hypersensitivity in human skin | Q57215013 |
| Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen | Q85664357 | ||
| Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain | Q88095844 | ||
| Neurotrophins and Neuropathic Pain: Role in Pathobiology | Q28084413 | ||
| The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands | Q28603128 | ||
| Local gene expression changes after UV-irradiation of human skin | Q28728091 | ||
| The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors | Q30488655 | ||
| Modulation of ultraviolet-induced hyperalgesia and cytokine upregulation by interleukins 10 and 13 | Q35042934 | ||
| Antagonism of nerve growth factor-TrkA signaling and the relief of pain | Q35064559 | ||
| Neurotrophins: mediators and modulators of pain. | Q36507606 | ||
| Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis. | Q36871346 | ||
| Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery | Q37087716 | ||
| Treatment of chronic non-cancer pain | Q37894414 | ||
| Brain-derived neurotrophic factor as a driving force behind neuroplasticity in neuropathic and central sensitization pain: a new therapeutic target? | Q38292331 | ||
| The use of baseline covariates in crossover studies | Q39128607 | ||
| Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain | Q39195605 | ||
| The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain | Q39263564 | ||
| Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology | Q40186234 | ||
| When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program | Q40337398 | ||
| p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia | Q42526677 | ||
| The use of a battery of pain models to detect analgesic properties of compounds: a two-part four-way crossover study. | Q47942829 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 301-309 | |
| P577 | publication date | 2017-11-28 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain models | |
| P478 | volume | 84 |
| Q92644368 | Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans |
| Q91806664 | Does in vitro potency predict clinical efficacious concentrations? |
| Q64275708 | Quantitative Systems Pharmacology and Empirical Models: Friends or Foes? |
| Q90828394 | The ultraviolet B inflammation model: Postinflammatory hyperpigmentation and validation of a reduced UVB exposure paradigm for inducing hyperalgesia in healthy subjects |
Search more.